Vandetanib for aggressive and symptomatic medullary thyroid cancer

Author： Deshpande Hari A   Carling Tobias   Khan Nabeela   Holt Elizabeth  

Publisher： Future Medicine

ISSN： 2044-9038

Source： Clinical Practice, Vol.10, Iss.3, 2013-05, pp. : 275-282

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Vandetanib in Advanced Medullary Thyroid Cancer: Review of Adverse Event Management Strategies

By Grande Enrique   Kreissl Michael   Filetti Sebastiano   Newbold Kate   Reinisch Walter   Robert Caroline   Schlumberger Martin   Tolstrup Lærke   Zamorano Jose   Capdevila Jaume  

Advances in Therapy, Vol. 30, Iss. 11, 2013-11 ,pp. : 945-966

Springer Publishing Company

Access to resources Recommend Favorite

Vandetanib‐associated alopecia areata in a patient with metastatic medullary thyroid cancer

By  

INTERNATIONAL JOURNAL OF DERMATOLOGY, Vol. 54, Iss. 6, 2015-06 ,pp. : e213-e216

John Wiley & Sons Inc

Access to resources Recommend Favorite

Medical management of metastatic medullary thyroid cancer

By  

CANCER, Vol. 120, Iss. 21, 2014-11 ,pp. : 3287-3301

John Wiley & Sons Inc

Access to resources Recommend Favorite

Medullary Thyroid Carcinoma

By  

Oncology Research and Treatment, Vol. 21, Iss. 4, 1998-09 ,pp. : 334-337

Karger

Access to resources Recommend Favorite

Integration of a postoperative calcitonin measurement into an anatomical staging system improves initial risk stratification in medullary thyroid cancer

By  

CLINICAL ENDOCRINOLOGY, Vol. 83, Iss. 6, 2015-12 ,pp. : 938-942

John Wiley & Sons Inc

Access to resources Recommend Favorite